Table 2.
OS in patients with iCCA
| Variable | FGFR2 fusions (n = 15) | No FGFR2 alterations (n = 109) | All patients with iCCA (n = 126)a |
|---|---|---|---|
| OS since diagnosis | |||
| Evaluable, n | 9 | 109 | 120 |
| Median (95% CI), months | 31.3 (5.8–NE) | 21.7 (16.1–26.6) | 22.5 (16.9–26.7) |
| OS since start of 1L therapy | |||
| Evaluable, n | 9 | 90 | 100 |
| Median (95% CI), months | 24.8 (3.4–NE) | 14.5 (12.2–20.2) | 15.1 (12.6–21.6) |
| OS since start of 2L therapy | |||
| Evaluable, n | 4 | 70 | 75 |
| Median (95% CI), months | 23.2 (10.8–NE) | 8.2 (6.5–14.6) | 10.4 (7.4–14.6) |
1L first-line, 2L second-line, CI confidence interval, FGFR2 fibroblast growth factor receptor 2, iCCA intrahepatic cholangiocarcinoma, NE not estimable, OS overall survival
aTwo patients with other FGFR2 alterations are not presented